Literature DB >> 6355009

Immunomodulation by bromocriptine.

E Nagy, I Berczi, G E Wren, S L Asa, K Kovacs.   

Abstract

Treatment of rats with the dopaminergic ergot alkaloid bromocriptine (BRC) inhibited the following immune reactions: contact sensitivity skin reaction to dinitrochlorobenzene (DNCB); antibody formation to sheep red blood cells and to bacterial lipopolysaccharide; adjuvant arthritis; and experimental allergic encephalitis. Immunosuppressive doses of BRC (5 mg/kg) decreased the serum prolactin (PRL) levels from 84.8 +/- 15.9 ng/ml to 4.9 +/- 1.6 ng/ml. Further studies on DNCB contact sensitivity and on antibody formation revealed that the immunocompetence of BRC-suppressed animals could be restored by additional treatment with either prolactin (PRL) or growth hormone (GH). Treatment with adrenocorticotropic hormone antagonized the restoring effect of PRL and GH. These results suggest that BRC suppressed immunity by its inhibition of PRL, and possibly also by inhibition of GH secretion.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6355009     DOI： 10.1016/0162-3109(83)90023-1

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN： 0162-3109


  27 in total

1.  Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus.

Authors:  Mansoor Karimifar; Afshin Tahmasebi; Zahra Sayed Bonakdar; Samaneh Purajam
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

Review 2.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

3.  GH3 pituitary adenoma cells can reverse thymic aging in rats.

Authors:  K W Kelley; S Brief; H J Westly; J Novakofski; P J Bechtel; J Simon; E B Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Why the gender difference in susceptibility to rheumatoid arthritis?

Authors:  P Brennan; A Silman
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

5.  Neonatal administration of prolactin antiserum alters the developmental pattern of T- and B-lymphocytes in the thymus and spleen of BALB/c female mice.

Authors:  D H Russell; K T Mills; F J Talamantes; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro.

Authors:  K Morkawa; F Oseko; S Morikawa
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  Elevated prolactin levels in human aqueous humor of patients with anterior uveitis.

Authors:  U Pleyer; D Gupta; E G Weidle; W Lisch; M Zierhut; H J Thiel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

8.  Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen.

Authors:  A R Buckley; P D Crowe; D H Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

9.  Activation of the prolactin receptor gene by promoter insertion in a Moloney murine leukemia virus-induced rat thymoma.

Authors:  C S Barker; S E Bear; T Keler; N G Copeland; D J Gilbert; N A Jenkins; R S Yeung; P N Tsichlis
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient.

Authors:  A Vidaller; F Guadarrama; L Llorente; J B Méndez; F Larrea; A R Villa; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.